Клиническое исследование

A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy

NCT: NCT06388707 · RECRUITING

NCT IDNCT06388707

СтатусRECRUITING

Дата начала2024-09-13

Завершение2027-10-31

SponsorNaviFUS Corporation (INDUSTRY)

First posted2024-04-29

Last updated2026-09-15

Краткое описание

This will be a prospective, open-label, single-arm, multi-center, pilot study to evaluate the safety, tolerability, and preliminary efficacy of low-intensity focused ultrasound (LIFU) neuromodulation using NaviFUS System in patients with drug-resistant unilateral or bilateral temporal lobe epilepsy (DR-TLE).

Официальный источник

Открыть на ClinicalTrials.gov →

Данные получены через API ClinicalTrials.gov. Актуальный статус смотрите в официальной записи.